3D Global Biotech Inc. (TPEX:6808)
Taiwan · Delayed Price · Currency is TWD 37.60
+0.60 (1.62%)
Aug 17, 2026, 1:43 PM CST
3D Global Biotech Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 159.19 | 206.74 | 265.69 | 20.63 | 13.64 | 11.08 | |
Revenue Growth | -51.00% | -22.19% | 1187.67% | 51.23% | 23.19% | -16.48% |
Cost of Revenue | 53.33 | 58.33 | 91.18 | 15.36 | 10.93 | 9.27 |
Gross Profit | 105.86 | 148.41 | 174.51 | 5.27 | 2.72 | 1.8 |
Selling, General & Admin | 54.92 | 56.38 | 42.54 | 29.53 | 29.53 | 26.41 |
Research & Development | 48.99 | 47.81 | 43.27 | 38.6 | 39.48 | 37.6 |
Operating Expenses | 112.01 | 106.96 | 86.02 | 68.13 | 69 | 64.01 |
Operating Income | -6.15 | 41.45 | 88.49 | -62.85 | -66.29 | -62.21 |
Interest Expense | -1.02 | -1.4 | -0.12 | -0.18 | -0.26 | -0.26 |
Interest & Investment Income | 10.6 | 13 | 6.19 | 2.24 | 1.68 | 1.35 |
Currency Exchange Gain (Loss) | -0.58 | -0.58 | 1.3 | 0.02 | -0.01 | 0 |
Other Non Operating Income (Expenses) | 16.6 | -0.79 | 0.14 | 1.85 | 0.62 | 0.15 |
EBT Excluding Unusual Items | 19.46 | 51.69 | 96 | -58.92 | -64.25 | -60.97 |
Gain (Loss) on Sale of Assets | - | - | 0 | - | - | - |
Asset Writedown | - | - | - | - | -18.89 | - |
Other Unusual Items | 0.62 | 0.62 | 0.07 | - | 0.01 | - |
Pretax Income | 20.08 | 52.31 | 96.07 | -58.92 | -83.13 | -60.97 |
Income Tax Expense | 5.89 | -14.22 | 4.37 | -0.96 | -16.05 | -1.26 |
Net Income | 14.2 | 66.53 | 91.7 | -57.95 | -67.09 | -59.71 |
Net Income to Common | 14.2 | 66.53 | 91.7 | -57.95 | -67.09 | -59.71 |
Net Income Growth | -89.40% | -27.45% | - | - | - | - |
Shares Outstanding (Basic) | 78 | 78 | 69 | 56 | 55 | 54 |
Shares Outstanding (Diluted) | 79 | 79 | 71 | 56 | 55 | 54 |
Shares Change | 0.57% | 11.92% | 26.08% | 2.32% | 1.69% | 0.77% |
EPS (Basic) | 0.18 | 0.86 | 1.33 | -1.03 | -1.22 | -1.11 |
EPS (Diluted) | 0.18 | 0.84 | 1.30 | -1.03 | -1.22 | -1.11 |
EPS Growth | -89.48% | -35.38% | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | 53.02 | 104.74 | 14.91 | -32.39 | -35.33 | -38.85 |
Free Cash Flow Per Share | 0.67 | 1.32 | 0.21 | -0.58 | -0.64 | -0.72 |
Dividend Per Share | 0.100 | 0.100 | 0.530 | - | - | - |
Dividend Growth | -81.13% | -81.13% | - | - | - | - |
Gross Margin | 66.50% | 71.79% | 65.68% | 25.56% | 19.91% | 16.28% |
Operating Margin | -3.86% | 20.05% | 33.31% | -304.62% | -485.87% | -561.71% |
Profit Margin | 8.92% | 32.18% | 34.52% | -280.87% | -491.73% | -539.10% |
Free Cash Flow Margin | 33.30% | 50.67% | 5.61% | -156.99% | -258.98% | -350.81% |
EBITDA | 7.99 | 58.16 | 104.62 | -46.49 | -47.15 | -42.46 |
EBITDA Margin | 5.02% | 28.13% | 39.38% | -225.30% | - | - |
D&A For EBITDA | 14.14 | 16.71 | 16.13 | 16.37 | 19.14 | 19.75 |
EBIT | -6.15 | 41.45 | 88.49 | -62.85 | -66.29 | -62.21 |
EBIT Margin | -3.86% | 20.05% | 33.31% | - | - | - |
Effective Tax Rate | 29.31% | - | 4.55% | - | - | - |